Market closedADR

Legend Biotech/$LEGN

14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX

About Legend Biotech

Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's lead product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.

Ticker

$LEGN
Sector
Health Care
Trading on
NASDAQ

Industry

Biotechnology
Headquarters
Somerset, United States

Employees

2,400
Website
www.legendbiotech.com

Legend Biotech Metrics

BasicAdvanced
$6B
-
-$1.92
0.16
-

$6B

0.16

$70.13

$30.17

1.4M

4.984

4.859

30.665

31.054

-15.76%

-12.28%

-28.35%

11.399

5.34

5.35

-33.657

122.96%

-35.35%

77.21%

-9.57%

What the Analysts think about Legend Biotech

Analyst Ratings

Analyst ratings (Buy, Hold, Sell) for Legend Biotech stock.

Legend Biotech Financial Performance

Income Statement

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

Legend Biotech Earnings Performance

Earnings per share (EPS)

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-

Legend Biotech News

AllArticlesVideos
Top 5 Commercial Biotech Buyout Candidates: Legend Biotech (No. 4)

Top 5 Commercial Biotech Buyout Candidates: Legend Biotech (No. 4)

Seeking Alpha·1 week ago
Legend Biotech to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Legend Biotech to Present at the 43rd Annual J.P. Morgan Healthcare Conference

GlobeNewsWire·4 weeks ago
CARVYKTI® Significantly Improved Minimal Residual Disease Negativity Compared to Standard of Care for Patients with Relapsed or Refractory Multiple Myeloma

CARVYKTI® Significantly Improved Minimal Residual Disease Negativity Compared to Standard of Care for Patients with Relapsed or Refractory Multiple Myeloma

GlobeNewsWire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $LEGN

$

Sign up or log in to buy
Capital at risk
Market closedADR

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Legend Biotech stock?

Legend Biotech (LEGN) has a market cap of $6B as of January 15, 2025.

What is the P/E ratio for Legend Biotech stock?

The price to earnings (P/E) ratio for Legend Biotech (LEGN) stock is 0 as of January 15, 2025.

Does Legend Biotech stock pay dividends?

No, Legend Biotech (LEGN) stock does not pay dividends to its shareholders as of January 15, 2025.

When is the next Legend Biotech dividend payment date?

Legend Biotech (LEGN) stock does not pay dividends to its shareholders.

What is the beta indicator for Legend Biotech?

Legend Biotech (LEGN) has a beta rating of 0.16. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.